<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2"><gtr:id>9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2</gtr:id><gtr:firstName>Gurdyal Singh</gtr:firstName><gtr:surname>Besra</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC56C359-8F37-4BAF-B2E4-8C55DC097D1A"><gtr:id>DC56C359-8F37-4BAF-B2E4-8C55DC097D1A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Lammas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400421"><gtr:id>922C454D-B145-4DAA-87AF-CE6BC10D1718</gtr:id><gtr:title>Modulation of immune responses by aGalCer analogues through differential activation of CD1d-restricted NKT cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400421</gtr:grantReference><gtr:abstractText>General statement. The proposed research will address fundamental questions about the biology of CD1d-restricted NKT cells and investigate ways to take advantage of both their immunostimulatory and immunoregulatory effects following activation by aGalCer or select analogues. By defining the pathways that are activated downstream of NKT by these agents we hope to develop a more rational strategy to exploit the diverse immunomodulatory properties of this family of compounds as potential immunotherapeutic drugs. As such, aGalCer and its analogues have potential use in three therapeutic areas. Firstly, the Th1 cytokine-inducing properties of aGalCer-based agents could provide protection against a variety of pathogens as a short-term immunostimulatory boost. Secondly, the non-specific immune activation properties of these compounds may be exploited as vaccine immunoadjuvants to boost cytotoxic responses to various neoplasias and infectious diseases. Thirdly, the Th2 cytokine-inducing properties of aGalCer and its analogues may prove effective at controlling auto-aggressive immune responses. 

Communication to the general public will be channelled through the University Press Office (http://www.newscentre.bham.ac.uk/office.htm), which has established contacts in the local and national media. In addition, academic staff at The University of Birmingham are available to provide comment and interpretation on key developments in science to the public, media and business through the ?Ask an Expert? scheme organised by the University Press Office. We will also present a summary of our work on our local web sites, which has open access.</gtr:abstractText><gtr:technicalSummary>CD1d-restricted Natural Killer T (NKT) cells are an important component of the innate immune system, which have the capacity to both augment beneficial host immunity and to prevent autoimmunity. The possibility of pharmacologically modulating both these innate functional activities of NKT to promote adaptive immune responses to treat disease states such as cancer and microbial infections, or conversely, to suppress autoimmune diseases is then extremely appealing. Administration of the synthetic glycolipid, a-galactosyl ceramide (aGalCer), is known to selectively activate CD1d-restricted NKT cells which has made this compound and its analogues attractive candidates for achieving such beneficial immunomodulatory effects. To this end we provide evidence that structurally modified forms of aGalCer exist which can evoke substantially altered responses from CD1d-restricted NKT cells both in vitro and in vivo. We propose to expand on these findings to develop synthetic compounds of aGalCer that have the capacity to differentially activate NKT in vitro which will further promote markedly different effects on the overall immune response in vivo. In order for this approach to be effective it is necessary to design compounds that have controlled and targeted affects and this requires an understanding of how these analogues differentially stimulate CD1d-restricted NKT cells to induce different functional outcomes. We propose firstly, to develop a panel of aGalCer analogues and screen them for NKT activating properties. Secondly, we will examine these analogues for both their differential presentation by specific cell types or tissues, and for their ability to induce expansion of NKT cells in vitro and in vivo. Thirdly, we will determine the mechanism(s) underlying the altered NKT responses to the aGalCer analogues. These studies will allow us to identify novel aGalCer derivatives, characterise their important immunological functions, and determine the mechanisms underlying their ability to induce diverse immunological responses. It is envisaged that such analogues will eventually be developed into a family of clinically useful immunomodulatory drugs.</gtr:technicalSummary><gtr:fund><gtr:end>2009-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>649683</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>New TB drugs?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>70D6BA89-CE6F-4637-9283-3979A7433612</gtr:id><gtr:impact>Interview and presentation for the BBC Inside Out

None</gtr:impact><gtr:outcomeId>D491B41401A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drug targets and vaccines</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9EF7E28F-B097-4523-8CD8-3081795A87A6</gtr:id><gtr:impact>An interview with the BBC Inside Out show.

None</gtr:impact><gtr:outcomeId>4652622D6AE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drugs and vaccines?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4C98CE2F-D520-41E3-A02A-47B00E656EC4</gtr:id><gtr:impact>Interview with the BBC and Inside Out Show for the West Midlands.

None</gtr:impact><gtr:outcomeId>DF6B35BD584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB Drugs</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9B1A3F28-9635-404A-8696-2F1C47E3A910</gtr:id><gtr:impact>Interview for BBC Inside Out.

None</gtr:impact><gtr:outcomeId>57DE7FE480A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>05551F2D-2B7B-4C9E-B0FF-DA4381BBDA76</gtr:id><gtr:impact>Interview and presentation on vaccines and new drug targets

None</gtr:impact><gtr:outcomeId>E001FED08EB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BCG Vaccine and problems?</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8FB5FFF4-32D7-4F8D-8106-974A348C375C</gtr:id><gtr:impact>BBC Inside Out

None</gtr:impact><gtr:outcomeId>0EBFE84C19D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>956647</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001750</gtr:fundingRef><gtr:id>C6FCB1F0-5254-4F70-B6F8-D1DB38350BFE</gtr:id><gtr:outcomeId>ekQXwtJEX5P</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1107601</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1C8D4B06-FA48-4E10-A364-33B989A267F8</gtr:id><gtr:outcomeId>H6m1ezPfu3M0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>569402</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (Novel invariant NKT cell agonists as adjuvants for antigen specific T and B cell responses)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E613F6AC-52BA-4E31-AA84-C353FE71BE95</gtr:id><gtr:outcomeId>528530F265B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A NP-derivative of galactosyl ceramide for cross talk between NKT and B cells</gtr:description><gtr:grantRef>G0400421</gtr:grantRef><gtr:id>36A371A3-5E05-4998-8C0D-1D8C7F7027EB</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>DCB09A0B6A0</gtr:outcomeId><gtr:patentId>WO2007051004?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Conjugate vaccines for non-proteinaceous antigens.</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Synthesis of a new analogue termed threitol ceramide</gtr:description><gtr:grantRef>G0400421</gtr:grantRef><gtr:id>0042CF32-7BEA-41A9-9DC0-B9F4289E81D5</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>DECF8CE4DDA</gtr:outcomeId><gtr:patentId>WO2007050668</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of a-galactosylceramide and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>New derivatives of galactosyl ceramide to promote Th1 responses, and cross-talk between NKT and B cells</gtr:description><gtr:id>579C84C4-0E42-4512-852C-64E0F18663BF</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>BEC79DC4369</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>galactosyl ceramide derivatives</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CFC19BA8-52B7-48C3-B730-A16ABE4F39E7</gtr:id><gtr:title>Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75309ee62fd0779a0c5559a240711098"><gtr:id>75309ee62fd0779a0c5559a240711098</gtr:id><gtr:otherNames>Stirnemann K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>9DFE7F4BC7D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5877989-FFA3-46CD-999B-5481DB88FF5A</gtr:id><gtr:title>Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bc11b4254344a4dc6f936c04e69c244"><gtr:id>7bc11b4254344a4dc6f936c04e69c244</gtr:id><gtr:otherNames>Sada-Ovalle I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>KpXzDVN7kLR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86A6D240-ECBD-413A-9283-25BB9CBB5088</gtr:id><gtr:title>Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eda599b4896f2b981d5bdb5f92f960f"><gtr:id>9eda599b4896f2b981d5bdb5f92f960f</gtr:id><gtr:otherNames>Im JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>5C6E5471708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60946A95-8F6E-4066-8B94-282E930656E9</gtr:id><gtr:title>PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afbf8d31ec5aade3e57fb546b0d6dfd1"><gtr:id>afbf8d31ec5aade3e57fb546b0d6dfd1</gtr:id><gtr:otherNames>Szatmari I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>E29165474B8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60142131-FB35-4FCE-9676-4400B7899D78</gtr:id><gtr:title>Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7cd142116be90487261484edef49239"><gtr:id>d7cd142116be90487261484edef49239</gtr:id><gtr:otherNames>Brennan PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>X5Yvs2b3Wb3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2E044FC-A2D5-4E09-BC5F-DD5EDF826734</gtr:id><gtr:title>Human CD4+ invariant NKT cells are involved in antibacterial immunity against Brucella suis through CD1d-dependent but CD4-independent mechanisms.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dd70f6c16a3e6c5a9adcbd74c93d69b"><gtr:id>1dd70f6c16a3e6c5a9adcbd74c93d69b</gtr:id><gtr:otherNames>Bessoles S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>E0F36A80C26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB273D74-0168-4554-9B2D-1945FC5D1BCF</gtr:id><gtr:title>NK T cells provide lipid antigen-specific cognate help for B cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6acd62da42995aa656526155f6ae4c1"><gtr:id>f6acd62da42995aa656526155f6ae4c1</gtr:id><gtr:otherNames>Leadbetter EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>AFE10868222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A7E7CD5-C0E7-49E3-8869-67FCCD09A53A</gtr:id><gtr:title>Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74aaa8e47112a3ae798b15a63c7ab34e"><gtr:id>74aaa8e47112a3ae798b15a63c7ab34e</gtr:id><gtr:otherNames>Guillonneau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>6FBA82E87A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6026895-534E-40FF-B3E3-B3DCD7EA9191</gtr:id><gtr:title>Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26134f681f6cf55c84202737dc3ce3e7"><gtr:id>26134f681f6cf55c84202737dc3ce3e7</gtr:id><gtr:otherNames>Kaur R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn><gtr:outcomeId>askjfMarhfh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CCA622B-8066-4F0A-BAFB-0016E23ADD11</gtr:id><gtr:title>Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ee56bb96a24f107fba1491c6fc1116f"><gtr:id>1ee56bb96a24f107fba1491c6fc1116f</gtr:id><gtr:otherNames>Muppidi JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>DQHDqiwwquc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4B37A81-E903-46EB-9092-686EA8A98B11</gtr:id><gtr:title>CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c20a6e13e22c8305e5467eb9ba6065a7"><gtr:id>c20a6e13e22c8305e5467eb9ba6065a7</gtr:id><gtr:otherNames>Chen YG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>D930C8260A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A28D704E-29F2-4F81-A8CC-EAFEED390C0D</gtr:id><gtr:title>A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5117f80274dd57ccd7e646e992afb3f3"><gtr:id>5117f80274dd57ccd7e646e992afb3f3</gtr:id><gtr:otherNames>Arora P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>Utf3SM3kUfB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4305C97B-808C-4898-B066-B5767BD09BA7</gtr:id><gtr:title>The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a3d14f806abdcc1cebb3b589a32041b"><gtr:id>7a3d14f806abdcc1cebb3b589a32041b</gtr:id><gtr:otherNames>McCarthy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>DC88A6D65DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68BC9B1D-B396-43A5-8E91-584FFE913BE0</gtr:id><gtr:title>An N-linked glycan modulates the interaction between the CD1d heavy chain and beta 2-microglobulin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e23ea203a121199e666fe65fb51d25fe"><gtr:id>e23ea203a121199e666fe65fb51d25fe</gtr:id><gtr:otherNames>Paduraru C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E98B944D6C8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E10387F2-4A41-41BE-820F-686C62E70A91</gtr:id><gtr:title>Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.</gtr:title><gtr:parentPublicationTitle>BMC immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fee4aab7f4a265e7ca4a053ad7853da"><gtr:id>4fee4aab7f4a265e7ca4a053ad7853da</gtr:id><gtr:otherNames>Croudace JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-2172</gtr:issn><gtr:outcomeId>B88A04F4EF4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42F751D1-90E6-4196-BE2A-75BC62DFF584</gtr:id><gtr:title>Recognition of ?-linked self glycolipids mediated by natural killer T cell antigen receptors.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b94b6b5326241e8dd79ebe2a97797720"><gtr:id>b94b6b5326241e8dd79ebe2a97797720</gtr:id><gtr:otherNames>Pellicci DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>gzjnP9F4Uh9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04020A42-93BE-4E38-AA00-9503A2367ED5</gtr:id><gtr:title>Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e0374cf703d528f0919afff7ec8853"><gtr:id>03e0374cf703d528f0919afff7ec8853</gtr:id><gtr:otherNames>Gadola SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>D2BF174F4A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9359B455-AF62-45D1-8E03-D8B549C327FC</gtr:id><gtr:title>Structures and functions of microbial lipid antigens presented by CD1.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f99e240216ed9db887216f4521b14157"><gtr:id>f99e240216ed9db887216f4521b14157</gtr:id><gtr:otherNames>Willcox BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>22FCD9337B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>258A424D-C938-48E2-BDE4-41A14B65B1A1</gtr:id><gtr:title>The bovine CD1 family contains group 1 CD1 proteins, but no functional CD1d.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d47083a7f870923cea9bf716967da545"><gtr:id>d47083a7f870923cea9bf716967da545</gtr:id><gtr:otherNames>Van Rhijn I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>CEB676B37ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C82AF23E-0791-49C1-BF24-3F85295A53F9</gtr:id><gtr:title>Synthesis of a novel alpha-galactosyl ceramide haptenated-lipid antigen, a useful tool in demonstrating the involvement of iNKT cells in the production of antilipid antibodies.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>g6QjSr3jSsS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137C336E-D215-4D54-8C66-25A16DCDE7BE</gtr:id><gtr:title>Mouse and human iNKT cell agonist ?-mannosylceramide reveals a distinct mechanism of tumor immunity.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4afba454087e49231bdc2d0eb5051138"><gtr:id>4afba454087e49231bdc2d0eb5051138</gtr:id><gtr:otherNames>O'Konek JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pLv9ifvBuJP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB089BDB-36FD-4BCC-9D1D-60E9544F83D0</gtr:id><gtr:title>Recognition of lyso-phospholipids by human natural killer T lymphocytes.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f69127b4fcfa9f2b2b188831d589d91"><gtr:id>6f69127b4fcfa9f2b2b188831d589d91</gtr:id><gtr:otherNames>Fox LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>F6A89ED2156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>622068B2-21D6-4129-A56F-080688730DA0</gtr:id><gtr:title>Rapid identification of immunostimulatory alpha-galactosylceramides using synthetic combinatorial libraries.</gtr:title><gtr:parentPublicationTitle>Journal of combinatorial chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f6924f8765fc02490873fd4b290945"><gtr:id>99f6924f8765fc02490873fd4b290945</gtr:id><gtr:otherNames>Li Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1520-4766</gtr:issn><gtr:outcomeId>B765CF4BA63</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D1916E-0D1D-4C77-9295-3D1E0097E011</gtr:id><gtr:title>Congenic analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7383d1458ff439483f8019cdc75827f4"><gtr:id>7383d1458ff439483f8019cdc75827f4</gtr:id><gtr:otherNames>Fletcher JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5C41F2A5E1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99723362-53AA-45EB-BB27-8B3BD8F56C90</gtr:id><gtr:title>Expression of CD1d molecules by human schwann cells and potential interactions with immunoregulatory invariant NK T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eda599b4896f2b981d5bdb5f92f960f"><gtr:id>9eda599b4896f2b981d5bdb5f92f960f</gtr:id><gtr:otherNames>Im JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>8B86C9B88C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>399516B2-BDAE-431D-B26B-A34AC9542EFE</gtr:id><gtr:title>Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a567e445f45cd9579c85c397f97b850e"><gtr:id>a567e445f45cd9579c85c397f97b850e</gtr:id><gtr:otherNames>McNab FW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>8E38E812044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0854107-8A08-4444-8776-B334F55E1D80</gtr:id><gtr:title>Lysosomal trafficking, antigen presentation, and microbial killing are controlled by the Arf-like GTPase Arl8b.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adbe95c148a74ac55927a59fd62ae6dd"><gtr:id>adbe95c148a74ac55927a59fd62ae6dd</gtr:id><gtr:otherNames>Garg S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>Q2N833peKsg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C636406A-B179-4D32-A478-9B434E2FA1EF</gtr:id><gtr:title>B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed032268c749fe13105b28653a67c1d5"><gtr:id>ed032268c749fe13105b28653a67c1d5</gtr:id><gtr:otherNames>Barral P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>35DF3DA0225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>308AF66E-064C-48D9-9170-A843F031FF59</gtr:id><gtr:title>NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e13c784cd812c8971c88b9a7d418b5"><gtr:id>52e13c784cd812c8971c88b9a7d418b5</gtr:id><gtr:otherNames>To K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>E613AE62288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6B92180-937E-407D-A7F6-08A5C3BCDE70</gtr:id><gtr:title>Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d09a00d7c724d63247a15b7e5419d9c5"><gtr:id>d09a00d7c724d63247a15b7e5419d9c5</gtr:id><gtr:otherNames>De Santo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>7C127CB92CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62D778C9-F38A-4054-8DB5-387BF7CAE79F</gtr:id><gtr:title>Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466f0b891ebe078be9ffb4023cd7bf15"><gtr:id>466f0b891ebe078be9ffb4023cd7bf15</gtr:id><gtr:otherNames>Sprengers D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>922D9535C44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D78CA934-4DEF-4F30-A012-E87347B038F4</gtr:id><gtr:title>Distinct requirements for CD1d intracellular transport for development of V(alpha)14 iNKT cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e64450745ea32ef41140173b1af77e8"><gtr:id>7e64450745ea32ef41140173b1af77e8</gtr:id><gtr:otherNames>Sill? FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>66646EECD22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1507897E-ADFB-4B4E-AD62-46D246945A68</gtr:id><gtr:title>Regulation of CD1 antigen-presenting complex stability.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7b3e51585c17d3c7b2615633fbef186"><gtr:id>b7b3e51585c17d3c7b2615633fbef186</gtr:id><gtr:otherNames>Odyniec AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>eoekfgDA2AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D18DA07E-92D8-45B2-A2B3-CE91FEB9CF35</gtr:id><gtr:title>Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f90146ab9ad82f90eb6c7de8f7e695b0"><gtr:id>f90146ab9ad82f90eb6c7de8f7e695b0</gtr:id><gtr:otherNames>Velmourougane G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>85837A2CEB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A2CCB65-895F-40FE-A96A-94326DF3132A</gtr:id><gtr:title>Synthesis and biological activity of alpha-L-fucosyl ceramides, analogues of the potent agonist, alpha-D-galactosyl ceramide KRN7000.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>JhZ6wr1qu7h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B8FB299-D0E7-4BE4-8A3A-1BC9E95B8B42</gtr:id><gtr:title>A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76ef329715f6e5d5f51f317067c0e75e"><gtr:id>76ef329715f6e5d5f51f317067c0e75e</gtr:id><gtr:otherNames>Montamat-Sicotte DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>KMpuYvSj2W7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7A65329-3387-401F-8BC2-94ED157417CF</gtr:id><gtr:title>Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80720ee1dde38ec2195b02c37e27d546"><gtr:id>80720ee1dde38ec2195b02c37e27d546</gtr:id><gtr:otherNames>Teng MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>6676EAE3664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9B1B035-4951-4499-9CFC-B9569AB876D8</gtr:id><gtr:title>Synthesis and biological activity of alpha-glucosyl C24:0 and C20:2 ceramides.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bc556e8a52dfe9b143535b3a1ef5857"><gtr:id>3bc556e8a52dfe9b143535b3a1ef5857</gtr:id><gtr:otherNames>Jervis PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>iJ1EzPLWmow</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC24A5C-B5AB-49C9-B610-B50B3C56C80F</gtr:id><gtr:title>Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eda599b4896f2b981d5bdb5f92f960f"><gtr:id>9eda599b4896f2b981d5bdb5f92f960f</gtr:id><gtr:otherNames>Im JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>F66372730EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4593765-70AB-4E0F-9A19-20930B034515</gtr:id><gtr:title>Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b66f0223bfec4b8d868bec5e4d2e491"><gtr:id>6b66f0223bfec4b8d868bec5e4d2e491</gtr:id><gtr:otherNames>Kuns RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>3D61E7F3724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E9F15A9-2808-43A2-A0FC-8571B383BF6C</gtr:id><gtr:title>IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c774aa62008712d42e52afde622e475c"><gtr:id>c774aa62008712d42e52afde622e475c</gtr:id><gtr:otherNames>Coquet JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>504A94DCE7F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13ED4593-0969-459E-86E3-A0D9B572590A</gtr:id><gtr:title>Rapid NKT cell responses are self-terminating during the course of microbial infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4aa2659060eb21eb9c2776bb269ee58"><gtr:id>b4aa2659060eb21eb9c2776bb269ee58</gtr:id><gtr:otherNames>Chiba A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>4F4ED6F29FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86DFDDF9-691C-4BF8-BBC1-B8261AAE2C93</gtr:id><gtr:title>Synthesis of truncated analogues of the iNKT cell agonist, a-galactosyl ceramide (KRN7000), and their biological evaluation.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>TMhV7TVNaUF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C591C332-F441-4916-9A81-FEE250774DA3</gtr:id><gtr:title>Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>24382CBA0C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99085C6D-1148-4C06-AF27-6BA4A40E9FCA</gtr:id><gtr:title>GATA-3 regulates the development and function of invariant NKT cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86a8e046f61705c8802310e7d3733870"><gtr:id>86a8e046f61705c8802310e7d3733870</gtr:id><gtr:otherNames>Kim PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>2B825D085B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38750076-F76B-48A4-9466-020EFCA2C099</gtr:id><gtr:title>Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddf82161d67c0fa2eac655b96e3f7189"><gtr:id>ddf82161d67c0fa2eac655b96e3f7189</gtr:id><gtr:otherNames>Molano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>938F22934AF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C8C81E-05E7-45E2-818C-9909DFB38CC7</gtr:id><gtr:title>Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76fc7c73e061efd4937e7e37e9d338ce"><gtr:id>76fc7c73e061efd4937e7e37e9d338ce</gtr:id><gtr:otherNames>Zeissig S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>DWGG2VpjEeK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA170172-F389-4903-A80E-6CDAF46276BC</gtr:id><gtr:title>Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a05e87dde9b7e5da94d0037d02d7a9ee"><gtr:id>a05e87dde9b7e5da94d0037d02d7a9ee</gtr:id><gtr:otherNames>Yuan W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>EBD7635B916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6606745-3434-4C15-8F08-C29346423710</gtr:id><gtr:title>Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad5bd11ee3ed44a0c44b2d88085a68dc"><gtr:id>ad5bd11ee3ed44a0c44b2d88085a68dc</gtr:id><gtr:otherNames>Brigl M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5A4BCDA6B89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D8799CD-C4C3-4CED-84A3-5F98A2713FD6</gtr:id><gtr:title>Crystal structure of bovine CD1b3 with endogenously bound ligands.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60c1670c61ad56cb052a51980e03a36"><gtr:id>c60c1670c61ad56cb052a51980e03a36</gtr:id><gtr:otherNames>Girardi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>eb25ic2ZFjM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C062C6FF-AC79-4B4F-B98C-1B1795DC19F2</gtr:id><gtr:title>Synthesis and biological activity of alpha-galactosyl ceramide KRN7000 and galactosyl (alpha1--&amp;gt;2) galactosyl ceramide.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>EF15845F3DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23AF2E6F-4A47-4F11-80CF-3586BD131B90</gtr:id><gtr:title>Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ca2f66195a33017606c80354324e501"><gtr:id>2ca2f66195a33017606c80354324e501</gtr:id><gtr:otherNames>Forestier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>2CF8480D043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCEB62D3-D971-4E45-A9FF-A53D5252BF29</gtr:id><gtr:title>NKT cells direct monocytes into a DC differentiation pathway.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25f81994da2454d1cb03e40966b961f9"><gtr:id>25f81994da2454d1cb03e40966b961f9</gtr:id><gtr:otherNames>Hegde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>B264BEB00BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D98EC0B5-6CD7-43D2-9EC4-E5578E190169</gtr:id><gtr:title>Modulation of CD1d-restricted NKT cell responses by CD4.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7771ec39b9bd63d704f50fabca5f24ae"><gtr:id>7771ec39b9bd63d704f50fabca5f24ae</gtr:id><gtr:otherNames>Chen X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>1848CA3AF1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA7DF87D-F52F-4CB9-93C1-EB186DFDFD51</gtr:id><gtr:title>Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f8c40a5123b3df4fd09d3c8aebd9b41"><gtr:id>3f8c40a5123b3df4fd09d3c8aebd9b41</gtr:id><gtr:otherNames>Yu KO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>D3BCF071092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8289350B-40C7-489C-ADA2-4626BDBC0CFA</gtr:id><gtr:title>Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7771ec39b9bd63d704f50fabca5f24ae"><gtr:id>7771ec39b9bd63d704f50fabca5f24ae</gtr:id><gtr:otherNames>Chen X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>63F89501AFE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>375CFB00-FE15-4587-B03A-EEB41A6EB76D</gtr:id><gtr:title>A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05359a4d7fecae86668836a1bda0abf"><gtr:id>d05359a4d7fecae86668836a1bda0abf</gtr:id><gtr:otherNames>Kjer-Nielsen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>3711F2D5F8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>312FA44A-FEBE-4D3A-9C1D-DAE8A685793E</gtr:id><gtr:title>?-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98e5e1c9df441ae573f55439793384f5"><gtr:id>98e5e1c9df441ae573f55439793384f5</gtr:id><gtr:otherNames>Bricard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>SP9nTFf6GgL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E379DC8B-E571-4196-9D2D-C73EEF39B166</gtr:id><gtr:title>Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d [corrected].</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acdaa5cffc4492b04b364947044a8b05"><gtr:id>acdaa5cffc4492b04b364947044a8b05</gtr:id><gtr:otherNames>Muindi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>NRWodJKYHBc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E4204A0-246A-48B4-81E9-7201C9C89B8D</gtr:id><gtr:title>Serum lipids regulate dendritic cell CD1 expression and function.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/519f746753369cc65826abb92db39d4e"><gtr:id>519f746753369cc65826abb92db39d4e</gtr:id><gtr:otherNames>Leslie DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>DFCD9B19871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>589BEDA2-D701-4F3C-89CC-491F62B8528D</gtr:id><gtr:title>Role of lipid trimming and CD1 groove size in cellular antigen presentation.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44bce12f82f64454d246ca688cc120f6"><gtr:id>44bce12f82f64454d246ca688cc120f6</gtr:id><gtr:otherNames>Cheng TY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>DD65390492A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A7EA239-90BD-424C-94D3-14C50B0FC42E</gtr:id><gtr:title>CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ff4da67370847bbcbb2e2212d30496a"><gtr:id>5ff4da67370847bbcbb2e2212d30496a</gtr:id><gtr:otherNames>Borg NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>00962FCD938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F31E04BA-8C30-4045-B348-46854A5D20D0</gtr:id><gtr:title>Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83d972dc5c6a23943bff292af7c649d9"><gtr:id>83d972dc5c6a23943bff292af7c649d9</gtr:id><gtr:otherNames>Denkberg G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5AFB6131C80</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400421</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>